TANVEX Trademark

Trademark Overview


On Friday, February 3, 2017, a trademark application was filed for TANVEX with the United States Patent and Trademark Office. The USPTO has given the TANVEX trademark a serial number of 87323906. The federal status of this trademark filing is REGISTERED as of Tuesday, May 25, 2021. This trademark is owned by Tanvex BioPharma, Inc.. The TANVEX trademark is filed in the Pharmaceutical Products category with the following description:

Anti-arthritis preparations; anti-inflammatory agent; anticancer drug; antirheumatic preparations; medicines for human purposes for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis; western medicines for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic ur...

General Information


Serial Number87323906
Word MarkTANVEX
Filing DateFriday, February 3, 2017
Status700 - REGISTERED
Status DateTuesday, May 25, 2021
Registration Number6358665
Registration DateTuesday, May 25, 2021
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, March 9, 2021

Trademark Statements


Description of MarkThe mark consists of the word "TANVEX" in the color light blue in stylized typeface.
Goods and ServicesAnti-arthritis preparations; anti-inflammatory agent; anticancer drug; antirheumatic preparations; medicines for human purposes for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis; western medicines for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis; medicinal agent for human use, namely, medicinal herbal preparations; biological preparations for medical purposes for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis; haematogen, namely, blood substitutes for human use; chemical preparations for medical purposes for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis; pharmaceutical drugs for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis; pharmaceutical preparations for treating diseases and medical conditions in the fields of dermatology, gastroenterology, hematology, infectious disease, oncology, and rheumatology, namely, neutropenia, breast cancer, gastric cancer, colorectal cancer, lung cancer, glioblastoma, carcinoma, arthritis, Crohn's disease, plaque psoriasis, asthma, chronic idiopathic urticaria, pararoxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and ankylosing spondylitis
Indication of Colors claimedThe color(s) light blue is/are claimed as a feature of the mark.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, February 8, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTanvex BioPharma, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressGrand Cayman KY1-1205
KY

Party NameTanvex BioPharma, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressGrand Cayman KY1-1205
KY

Party NameTanvex BioPharma, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressGrand Cayman KY1-1205
KY

Trademark Events


Event DateEvent Description
Tuesday, February 7, 2017NEW APPLICATION ENTERED
Wednesday, February 8, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, February 23, 2017TEAS VOLUNTARY AMENDMENT RECEIVED
Friday, March 10, 2017ASSIGNED TO LIE
Thursday, March 30, 2017PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Saturday, April 29, 2017ASSIGNED TO EXAMINER
Saturday, May 6, 2017PRIORITY ACTION WRITTEN
Saturday, May 6, 2017PRIORITY ACTION E-MAILED
Saturday, May 6, 2017NOTIFICATION OF PRIORITY ACTION E-MAILED
Wednesday, September 20, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, September 25, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, September 25, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, October 2, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 25, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 14, 2017PUBLISHED FOR OPPOSITION
Tuesday, November 14, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 9, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, May 2, 2018TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, May 2, 2018SOU TEAS EXTENSION RECEIVED
Wednesday, May 2, 2018SOU EXTENSION 1 FILED
Wednesday, May 2, 2018SOU EXTENSION 1 GRANTED
Friday, May 4, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 24, 2018SOU TEAS EXTENSION RECEIVED
Monday, December 24, 2018SOU EXTENSION 2 FILED
Monday, December 24, 2018SOU EXTENSION 2 GRANTED
Wednesday, December 26, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 5, 2019SOU TEAS EXTENSION RECEIVED
Wednesday, June 5, 2019SOU EXTENSION 3 FILED
Wednesday, June 5, 2019SOU EXTENSION 3 GRANTED
Friday, June 7, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 8, 2019ASSIGNED TO EXAMINER
Friday, December 27, 2019SOU TEAS EXTENSION RECEIVED
Friday, December 27, 2019SOU EXTENSION 4 FILED
Friday, December 27, 2019SOU EXTENSION 4 GRANTED
Tuesday, December 31, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 2, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, July 2, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, July 2, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 2, 2020TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, July 2, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, July 2, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, July 2, 2020SOU TEAS EXTENSION RECEIVED
Thursday, July 23, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, July 2, 2020SOU EXTENSION 5 FILED
Monday, July 27, 2020SOU EXTENSION 5 GRANTED
Tuesday, July 28, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 18, 2020TEAS PETITION TO AMEND BASIS RECEIVED
Monday, January 4, 2021ASSIGNED TO PETITION STAFF
Monday, January 4, 2021PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
Monday, January 4, 2021ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED
Monday, January 11, 2021NOTICE OF ALLOWANCE CANCELLED
Wednesday, February 17, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 9, 2021PUBLISHED FOR OPPOSITION
Tuesday, March 9, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 25, 2021REGISTERED-PRINCIPAL REGISTER
Monday, May 25, 2026COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED